Trump Says Anthropic No Longer Seen as National Security Threat 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2016 -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, announced today that it has joined over 80 pharmaceutical, biotechnology, and diagnostics companies in drafting and signing the Declaration on Combating Antimicrobial Resistance. The Declaration – which highlights the continued increase of bacterial resistance to antibiotics and the urgent need to develop new, innovative drugs – is a call to action, outlining specific initiatives that governments and industry can implement in a collaborative effort to further address the threat of Antimicrobial Resistance (AMR). This initiative further demonstrates Achaogen’s commitment to economic, regulatory, and reimbursement reform toward establishing a sustainable solution that incentivizes the development and commercialization of novel antibiotics addressing the unmet need of treating drug resistant infections.
“Achaogen is focused on the discovery and development of new antibacterials to treat multi-drug resistant, gram-negative infections and is committed to participating in the coordinated global action required to address the public health threat posed by AMR,” said Kenneth Hillan, Achaogen’s Chief Executive Officer. “We applaud the efforts of Lord O’Neill’s Review on AMR and are pleased to support this Declaration and the call for collective global measures to overcome the barriers to the development and commercialization of life-saving antibiotics.”
The Declaration, along with a complete list of signatories, is available at the Review on AMR website at www.amr-review.org/industry-declaration.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious urinary tract, lung, and bloodstream infections due to Enterobacteriaceae, including CRE. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
Contact Candice Knoll Blueprint Life Science Group 415.375.3340 Ext. 4 [email protected]
